Preloaded DMEK EndoGlide™ offers surgeons a fourth preloaded DMEK option to streamline surgery, reduce cost

Preloaded DMEK EndoGlide™ now available from Eversight

ANN ARBOR, Mich., April 5, 2023Eversight, a leading global nonprofit eye bank, today announced the availability of Descemet’s membrane endothelial keratoplasty (DMEK) tissue preloaded in EndoGlide, offering corneal surgeons a fourth preloaded DMEK option to further streamline surgery and reduce cost.

As illustrated, preloaded DMEK EndoGlide™ utilizes an endothelium-in or trifold loading method, whereas traditional injectable DMEK grafts are loaded endothelium-out. Using an anterior chamber maintainer for infusion, the graft is pulled into the eye with specialized forceps through a 2.65mm incision. The DMEK graft has a natural tendency to unscroll in the correct orientation because it was loaded endothelium-in.


The pull-through technique and endothelium-in attribute of preloaded DMEK EndoGlide™ provide added control of the graft and its orientation, which is critical to the success of the procedure and may make DMEK more achievable in complex eyes.

“DMEK provides favorable clinical outcomes for patients and is an efficient use of surgeon time and healthcare resources,” said Michael Titus, Vice President of Clinical Operations, Eversight. “As adoption of DMEK continues to grow, we listened to surgeons who aim to make the procedure available to more of their patients. Eversight is dedicated to providing improved tissue preparation services like preloaded DMEK EndoGlide™ that can ultimately improve access to quality eye care.”

Contact your Eversight representative to learn more about DMEK in EndoGlide™—one of four preloaded DMEK options available from Eversight—and access free on-demand training to confidently adopt this surgical technique.

About Eversight
Eversight is a nonprofit organization with a mission to restore sight and prevent blindness through the healing power of donation, transplantation and research. The Eversight network is responsible for recovering, evaluating and providing human eye tissue for transplantation; supporting research into the causes and cures of blinding eye conditions; promoting donation awareness through public and professional education; and providing humanitarian aid to people around the world in need of corneal transplantation. Operating in Connecticut, Illinois, Michigan, New Jersey, Ohio and South Korea, Eversight works in collaboration with surgeons, researchers, academic medical centers and eye banks across the United States and abroad. For more information, visit

Media Contact
Mackenzie Mohr
Communications Director
(517) 204-1413

In this season of gratitude, Eversight has launched a matching


campaign to impact even more lives. Please consider supporting Eversight and help us earn a generous $4,000 match from our Board of Directors.

Stay in touch

Help us tailor your Eversight experience by subscribing to information that is meaningful to you.
Subscribe now